Kindstar Globalgene Technology, Inc. (KDGTF)
Kindstar Globalgene Technology, Inc. operates in the Medical - Care Facilities industry of the Healthcare sector, headquartered in Wuhan, CN. The stock last traded at $0.68, up 0.00% on the session, giving a market capitalisation of $675.1M. On trailing twelve-month figures it carries a trailing P/E of -13.66, a net margin of -6.3%. Its beta of 0.00 implies it has historically moved less than the broad market.
Kindstar Globalgene Technology, Inc. delivers advanced, specialized diagnostic testing solutions to hospitals throughout China. These sophisticated services are designed to assist clinical specialist physicians across a range of medical fields, including hematological oncology, rare genetic conditions, obstetrics and gynecology, neurological disorders, infectious diseases, and solid tumor analysis, among others. The company's tests play a crucial role in the early identification, prevention, and precise diagnosis of complex diseases, as well as in guiding treatment selections and evaluating the efficacy of therapeutic interventions. Its extensive laboratory infrastructure encompasses facilities for flow cytometry, cytogenetics, medical genomics, molecular biology, hematopathology, mass spectrometry, general pathology, clinical immunology, microbiology, and various other specialized diagnostic techniques. Founded in 2003, the company maintains its headquarters in Wuhan, China.
Kindstar Globalgene Technology, Inc. is most often compared with the following Healthcare names: